OR WAIT 15 SECS
Several “What’s New” factors will help dermatologists optimize photodynamic therapy in the treatment of actinic keratoses.
In his presentation yesterday (Saturday, Oct. 3) at the Fall Clinical Dermatology Conference, Brian Berman, M.D., Ph.D., updated the audience on “PDT: What’s New and What’s Important.”
Dr. Berman discussed how to optimize photodynamic therapy (PDT) in the treatment of actinic keratoses (AK). He said several “What’s New” factors will help dermatologists accomplish that optimization.
Dr. Berman says today’s PDT is characterized by several new trends:
Of these, he says, the “What’s Important”-or most important-advancements are two-fold: “Increased efficacy with occlusion of extremity AKs, and ‘painless’ PDT.”
Dr. Berman is co-director of Skin & Cancer Associates, Aventura, Fla., and also serves as voluntary professor of dermatology and cutaneous surgery at the University of Miami Miller School of Medicine.